Tamoxifen and cardiovascular risk
Farge, D.; Chanu, B.; Debourdeau, P.; Sauvaget, F.; Espie, M.; Gorins, A.; Rouffy, J.
Annales de Medecine Interne 145(7): 488-493
1994
ISSN/ISBN: 0003-410X PMID: 7864520 Document Number: 428054
Document emailed within 1 workday
Related Documents
Sharma, D.; Sharma, U.; Bhatnagar, V.B.; Singh, V.S. 2001: A study of the effect of tamoxifen on serum lipoprotein profiles in premenopausal and postmenopausal women with breast carcinoma and associated risk of cardiovascular disease Indian Journal of Medical Sciences 55(7): 359-365Chiesa, M.Dalla.; Passalacqua, R.; Michiara, M.; Franciosi, V.; Di Costanzo, F.; Bisagni, G.; Camisa, R.; Buti, S.; Tomasello, G.; Cocconi, G. 2007: Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial Acta Bio-Medica: Atenei Parmensis 78(3): 204-209
Kleber, M.E.; Winkler, K.; Wolfert, R.L.; Delgado, G. de Moissl; Grammer, T.B.; Dietz, S.; Winkelmann, B.R.; Boehm, B.O.; Winfried März 2011: Lipoprotein Associated Phospholipase A2 Concentration Predicts Total and Cardiovascular Mortality Independently of Established Risk Factors (The Ludwigshafen Risk and Cardiovascular Health Study) Clinical Laboratory 57(9-10): 659-667
Baena Díez, Jé.Miguel.; Del Val García, Jé.Luis.; Alemany Vilches, L.; Martínez Martínez, Jé.Luis.; Tomàs Pelegrina, J.; González Tejón, Ián.; Raidó Quintana, E.María.; Rovira España, Mónica. 2005: Risk of Suffering from Cardiovascular Diseases because of the Clustering of the Modifiable Cardiovascular Risk Factors in the Population Older than 15 years of a Health Care Center in Barcelona Revista espanola de salud publica 79: 365-378
Osler, M.; Jespersen, N.B.; Lous, J.; Rasmussen, N.K. 1992: Cardiovascular risk factors--extent and self-assessed risk in relation to prevention of cardiovascular diseases. A questionnaire among 3,956 men and women aged 24-65 years in Vejle County, Slangerup and Helsinge municipalities Ugeskrift for Laeger 154(9): 538-543
Morrow, M.; Jordan, V.C. 1993: Risk factors and the prevention of breast cancer with tamoxifen Cancer Surveys 18: 211-229
Palmieri, L.; Trojani, M.; Vanuzzo, D.; Panico, S.; Pilotto, L.; Dima, F.; Noce, C.L.; Uguccioni, M.; Pede, S.; Giampaoli, S. 2005: Distribution of the global cardiovascular risk in the Italian population: results from the cardiovascular epidemiologic observatory Italian Heart Journal. Suppl: Official Journal of the Italian Federation of Cardiology 6(5): 279-284
Lowe, G.; Rumley, A.; Norrie, J.; Ford, I.; Shepherd, J.; Cobbe, S.; Macfarlane, P.; Packard, C. 2000: Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study Thrombosis and Haemostasis 84(4): 553-558
Powles, T.J.; Gordon, C.; Coombes, R.C. 1982: Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone Cancer Research 42(8 Suppl): 3458s-3460s
Semiglazov, V.F.; Maximov, S.Y.; Bulgatova, Y., A.; Meshkova, I.Y.; Chepik, O.F.; Berstein, L.M. 2003: Risk of hyperplasia and endometrial carcinoma in breast cancer patients receiving adjuvant tamoxifen Voprosy Onkologii (Stsburg). 49(2): 198-204
Vrhovski, D.; Mestrić, Z.; Subić, N.; Surina, B.; Kranjcević, S. 1985: Established risk factors and complementary risk factors as additional parameters in evaluating the risk of cardiovascular diseases Lijecnicki Vjesnik 107(11-12): 481-484
Fellah, H.; Feki, M.; Feki, H.; Souissi, M.; Kaabachi, N.; Abdallah, T.B.; Massy, Z.A.; Maiz, H.B.; Lacour, B.; Mebazaa, A. 2004: Classical and "Non-classical" Cardiovascular Risk Factors in Tunisian Patients with End Stage Renal Disease: Prevalence and Association with Cardiovascular Events Clinical Laboratory 50(7-8): 447-453
Mustacchi, G.; Milani, S.; Pluchinotta, A.; De Matteis, A.; Rubagotti, A.; Perrota, A. 1994: Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly Anticancer Research 14(5b): 2197-2200
Oksa, A. 2006: Cardiovascular risk in patients with chronic kidney diseases: a time for new risk markers? Bratislavske Lekarske Listy 107(8): 314-319
Tonstad, S. 1998: Should treatment of risk factors of cardiovascular diseases be directed only by absolute risk? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 118(19): 2966-2968
Elliott, H.L. 1998: Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? Journal of Cardiovascular Pharmacology 32(Suppl 3): S74-S77
Edwards-Jackson, N.; Kerr, S.; Tieu, H.; Ananworanich, J.; Hammer, S.; Ruxrungtham, K.; Phanuphak, P.; Avihingsanon, A. 2011: Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais HIV Medicine 12(8): 510-515
Rosales-Alexander, J.L.; Salvatierra, J.; Llorca, J.; Magro-Checa, C.; González-Gay, M.A.; Cantero-Hinojosa, J.; Raya-Álvarez, E. 2014: Cardiovascular risk assessment in rheumatoid arthritis: impact of the EULAR recommendations on a national calibrated score risk index Clinical and Experimental Rheumatology 32(2): 237-242
Protopopova, D.; Masopust, J.; Maly, R.; Valis, M.; Bazant, J. 2012: The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders Psychiatria Danubina 24(3): 307-313
Lakka, H.M.; Lakka, T.A.; Tuomilehto, J.; Sivenius, J.; Salonen, J.T. 2000: Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study Archives of Internal Medicine 160(8): 1160-1168